Ross Muken
Stock Analyst at Evercore ISI Group
(1.89)
# 3,155
Out of 5,182 analysts
49
Total ratings
53.57%
Success rate
-1.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ross Muken
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: Outperform | $260 → $200 | $173.89 | +15.02% | 11 | Feb 19, 2026 | |
| HSIC Henry Schein | Maintains: In-Line | $78 → $70 | $73.94 | -5.33% | 10 | Aug 6, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $170 → $240 | $114.19 | +110.18% | 9 | Jul 25, 2025 | |
| A Agilent Technologies | Maintains: In-Line | $126 → $130 | $115.48 | +12.57% | 11 | Jul 2, 2024 | |
| QGEN Qiagen | Downgrades: In-Line | n/a | $41.03 | - | 2 | Jul 16, 2019 | |
| CAH Cardinal Health | Initiates: In-Line | $67 | $214.05 | -68.70% | 2 | Jan 5, 2018 | |
| ILMN Illumina | Initiates: Outperform | $250 | $127.38 | +96.26% | 2 | Jan 4, 2018 | |
| TMO Thermo Fisher Scientific | Initiates: Outperform | $220 | $491.46 | -55.24% | 1 | Jan 4, 2018 | |
| MBLY Mobileye Global | Downgrades: In-Line | n/a | $7.45 | - | 1 | Mar 13, 2017 |
Charles River Laboratories International
Feb 19, 2026
Maintains: Outperform
Price Target: $260 → $200
Current: $173.89
Upside: +15.02%
Henry Schein
Aug 6, 2025
Maintains: In-Line
Price Target: $78 → $70
Current: $73.94
Upside: -5.33%
ICON Public Limited Company
Jul 25, 2025
Maintains: Outperform
Price Target: $170 → $240
Current: $114.19
Upside: +110.18%
Agilent Technologies
Jul 2, 2024
Maintains: In-Line
Price Target: $126 → $130
Current: $115.48
Upside: +12.57%
Qiagen
Jul 16, 2019
Downgrades: In-Line
Price Target: n/a
Current: $41.03
Upside: -
Cardinal Health
Jan 5, 2018
Initiates: In-Line
Price Target: $67
Current: $214.05
Upside: -68.70%
Illumina
Jan 4, 2018
Initiates: Outperform
Price Target: $250
Current: $127.38
Upside: +96.26%
Thermo Fisher Scientific
Jan 4, 2018
Initiates: Outperform
Price Target: $220
Current: $491.46
Upside: -55.24%
Mobileye Global
Mar 13, 2017
Downgrades: In-Line
Price Target: n/a
Current: $7.45
Upside: -